Cited by 81Clusterin in disease pathologyTGF-β signaling in diseasesCancer Cells and Metastasis

Transcriptome profiling of a TGF-β-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies

Open access
Lenferink, A E G, Cantin, C, Nantel, A, Wang, E, Durocher, Y, Banville, M, Paul-Roc, B, Marcil, A +2 more·2010·Oncogene

Abstract

Transforming growth factor (TGF)-beta plays a dual role in tumorigenesis, switching from acting as a growth inhibitory tumor suppressor early in the process, to a tumor promoter in late-stage disease. Since TGF-beta's prometastatic role may be linked to its ability to induce tumor cell epithelial-to-mesenchymal transition (EMT), we explored TGF-beta's EMT-promoting pathways by analysing the transcriptome changes occurring in BRI-JM01 mammary tumor epithelial cells undergoing a TGF-beta-induced EMT. We found the clusterin gene to be the most highly upregulated throughout most of the TGF-beta time course, and showed that this results in an increase of the secreted form of clusterin. By monitoring several hallmark features of EMT, we demonstrated that antibodies targeting secreted clusterin inhibit the TGF-beta-induced EMT of BRI-JM01 cells, as well as the invasive phenotype of several other breast and prostate tumor cell lines (4T1, NMuMG, MDA-MB231LM2 and PC3), without affecting the proliferation of these cells. These results indicate that secreted clusterin is a functionally important EMT mediator that lies downstream within TGF-beta's EMT-promoting transcriptional cascade, but not within its growth-inhibitory pathways. To further investigate the role played by secreted clusterin in tumor metastasis, we assessed the effect of several anti-clusterin monoclonal antibodies in vivo using a 4T1 syngeneic mouse breast cancer model and found that these antibodies significantly reduce lung metastasis. Taken together, our results reveal a role for secreted clusterin as an important extracellular promoter of EMT, and suggest that antibodies targeting clusterin may inhibit tumor metastasis without reducing the beneficial growth inhibitory effects of TGF-beta.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2009.399

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In other in vitro systems, TGFβ promotes axonal outgrowth of injured neurons and blockade of TGFβRII alters neuronal polarity and leads to shorter axons.

    “In other in vitro systems, TGFβ promotes axonal outgrowth of injured neurons21,22,39,40 and blockade of TGFβRII alters neuronal polarity and leads to shorter axons42.”

    From GDF10 is a signal for axonal sprouting and functional recovery after stroke (2015) · cites this paper as [42]

    The Introduction describes TGF-β signaling, and the section on BRI-JM01 cells examines epithelial-to-mesenchymal transition in a mammary tumor cell line. Searches for injured neurons, axonal outgrowth, neuronal polarity, and TGF-βRII blockade found no passage addressing either neuronal claim; the cited paper cannot verify them. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lenferink, A. E. G., Cantin, C., Nantel, A., Wang, E., Durocher, Y., Banville, M., Paul-Roc, B., Marcil, A., Wilson, M. R., & O'Connor-McCourt, M. D.
Affiliations
  • Biotechnology Research Institute (CA)
  • University of Wollongong (AU)
Corresponding author
Lenferink, A E G
Venue
Oncogene
Published
2009-11-23
Volume
29
Issue
6
Pages
831-844
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2079135826
Cited by
81
References
89
Citations by year
2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2019: 5 · 2018: 2 · 2017: 8 · 2016: 4 · 2015: 7 · 2014: 11 · 2013: 8 · 2012: 10
FWCI
3.78
Type
journal article
Language
en
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
  • NPARC (submittedVersion)
  • Research Online (University of Wollongong) (submittedVersion)
Funders
University Health Network
Topics
  • Health Sciences › Medicine › Oncology › Clusterin in disease pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
TGF-beta, epithelial-mesenchymal transition, metastasis, breast cancer, prostate cancer, lung metastasis, tumor invasion
MeSH terms
Animals, Antibodies, Antibodies, Monoclonal, Breast Neoplasms, Cell Movement, Epithelial Cells, Extracellular Space, Female, Humans, Immunoglobulin G, Lung Neoplasms, Mesoderm, Mice, Inbred BALB C, Phenotype, RNA, Messenger, Transcription, Genetic, Reproducibility of Results, Transforming Growth Factor beta, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Cell Line, Tumor, Cell Proliferation, Clusterin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review